HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
United Kingdom Health OTC Drugs

Sanofi Switch Gives UK Hay Fever Sufferers Additional Mass Market Option

  • News

Executive Summary

Sanofi has switched its Allevia hay fever tablets (fexofenadine hydrochloride) in the UK, from prescription-only to general sales list status. 

You may also be interested in...



Sanofi Pulls Allevia 'Non-Drowsy' Claim Following MHRA Probe

Sanofi's claim in a TV ad that its Allevia hay fever tablets were non drowsy contradicted the drug's summary of product characteristics, found an investigation by the UK's Medicines and Healthcare products Regulatory Agency.

Sanofi’s Nasacort Hay Fever Spray Latest In Post-Brexit UK Switch Boom

Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.

Cipla Switches Fexofenadine For Hives From Rx-To-OTC Status In The UK

UK hives sufferers can now buy a specific OTC medicine for their condition thanks to a successful Rx-to-OTC switch from Cipla. 

Table

View full table

Related Content

HBW Insight

Topics

Tags:
United Kingdom Health OTC Drugs
Latest Headlines

Cosmetic And Personal Care Weekly Trademarks Review: 28 November

The Future Of US FDA’s Institutional Memory

US State Laws To Address Packaging Waste Are Cosmetics Industry’s Newest Patchwork Problem

EA Pharma Enters US And Launches Olyos Group

See All
UsernamePublicRestriction

Register

RS150856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By